ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 99 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $429,000 | -67.0% | 58,110 | -35.1% | 0.20% | -54.4% |
| Q3 2018 | $1,300,000 | -12.0% | 89,500 | +21.0% | 0.43% | -16.0% |
| Q2 2018 | $1,477,000 | +90.8% | 73,985 | +67.4% | 0.51% | +86.2% |
| Q1 2018 | $774,000 | -32.0% | 44,200 | -4.3% | 0.28% | -32.8% |
| Q4 2017 | $1,139,000 | +6.1% | 46,200 | +11.1% | 0.41% | +0.2% |
| Q3 2017 | $1,074,000 | +3.2% | 41,600 | +8.3% | 0.41% | -1.9% |
| Q2 2017 | $1,041,000 | +6.6% | 38,400 | +17.3% | 0.42% | +0.7% |
| Q1 2017 | $977,000 | +70.2% | 32,750 | +54.8% | 0.41% | +52.4% |
| Q4 2016 | $574,000 | – | 21,150 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |